Summary
There have previously been divergent data published regarding the effects of glucose on the diabetogenic effects of streptozotocin. In order to further explore this issue, two separate sets of experiments were performed. In the first, mouse pancreatic islets were maintained in culture for 3 days at different glucose concentrations (5.6,11.1 and 28 mmol/l) and then exposed to streptozotocin. After another 3 days in culture at 11.1 mmol/l glucose, the B cell function was evaluated by measurement of glucose-stimulated insulin release, the number of islets recovered after culture, and the islet DNA and insulin contents. In the second group of experiments islets were first maintained in culture at 11.1 mmol/l glucose, then treated with streptozotocin and subsequently cultured for 6 days at the different glucose concentrations given above. It was found that islets maintained in a medium containing 28 mmol/l glucose before or after streptozotocin exposure showed less signs of damage than islets cultured in 11.1 mmol/l glucose. A similar, but less pronounced, de creased sensitivity to streptozotocin was found in islets precultured in 5.6 mmol/l glucose, in comparison with those islets cultured in 11.1 mmol/l glucose. Culture at 5.6 mmol/l glucose just after streptozotocin treatment did not induce any improvement in islet survival or function. It is suggested that the increased damage induced by streptozotocin to islets precultured at 11.1 mmol/l glucose, in comparison with 5.6 mmol/l glucose, can be related to the fact that an increased metabolic activity of B cells render them more susceptible to the toxin. The improved preservation of islets cultured at 28 mmol/l glucose before or after streptozotocin treatment may reflect an additional effect of glucose, i. e. activation of defense mechanisms in the B cells against cytotoxins.
Article PDF
Similar content being viewed by others
References
Cahill GF, McDevitt HO (1981) Insulin-dependent diabetes: the initial lesion. N Engl J Med 304: 1454–1465
Rerup CC (1970) Drugs producing diabetes through damage of the insulin secreting cells. Pharmacol Rev 22: 485–518
Like AA, Rossini AA (1976) Streptozotocin-induced pancreatic insulitis: a new model of diabetes mellitus. Science 193: 415–417
Eizirik DL, Migliorini RH (1984) Reduced diabetogenic effect of streptozotocin in rats previously adapted to a high-protein, carbohydrate-free diet. Diabetes 33: 383–388
Eizirik DL, Boschero AC, Migliorini RH (1985) Previous adaptation to a high-protein diet protects against streptozotocin-induced inhibition of insulin release from isolated rat islets. Brazilian J Med Biol Res 18: 233–235
Dulin WE, Wyse BM (1969) Studies on the ability of compounds to block the diabetogenic activity of streptozotocin. Diabetes 18: 459–466
Zawalich WS, Beilder LM (1973) Glucose and alloxan interactions in the pancreatic islets. Am J Physiol 224: 963–966
Ganda OP, Rossini AA, Like AA (1976) Studies on streptozotocin diabetes. Diabetes 25: 595–603
Brodsky C, Logothetopoulos J (1969) Streptozotocin diabetes in the mouse and guinea pig. Diabetes 18: 606–611
Sandler S, Andersson A (1982) The partial protective effect of the hydroxyl radical scavenger dimethyl urea on streptozotocin-induced diabetes in the mouse in vivo and in vitro. Diabetologia 23: 374–378
Sandler S, Andersson A (1985) Modulation of streptozotocininduced insulitis and hyperglycaemia in the mouse. Acta Path Microbiol Immunol Scand [A] 93: 93–98
Jansson L, Sandler S (1985) Pancreatic islet circulation in relation to the diabetogenic action of streptozotocin in the rat. Endocrinology 116: 896–900
Okamoto H (1981) Regulation or proinsulin synthesis in pancreatic islets and a new aspect to insulin-dependent diabetes. Mol Cell Biochem 37: 43–61
Maldonato A, Trueheart PA, Renold AE, Sharp GWG (1976) Effects of streptozotocin in vitro on proinsulin biosynthesis, insulin release and ATP content of isolated rat islets of Langerhans. Diabetologia 12: 471–481
Sandler S, Welsh M, Andersson A (1983) Streptozotocin-induced impairment of islet B-cell metabolism and its prevention by a hydroxyl radical scavenger and inhibitor of poly(ADP-ribose) synthetase. Acta Pharmacol Toxicol 53: 392–400
Howell SL, Taylor KW (1968) Potassium ions and the secretion of insulin by islets of Langerhans incubated in vitro. Biochem J 108: 17–24
Lernmark Å, Nathans A, Steiner DF (1976) Preparation and characterization of plasma membrane-enriched fractions from pancreatic islets. J Cell Biol 17: 606–623
Krebs HA, Henseleit K (1932) Untersuchungen über die Harnstoffbildung im Tierkörper. Hoppe-Seylers Z Physiol Chem 210: 33–66
Keen H, Field JB, Pastan IH (1963) A simple method for in vivo metabolic studies using small volumes of tissue and medium. Metabolism 12: 143–147
Heding LG (1972) Determination of total serum insulin (IRI) in insulin-treated patients. Diabetologia 8: 260–266
Kissane JM, Robins E (1958) The fluorimetric measurement of deoxyribonucleic acid in animal tissues with special reference to the central nervous system. J Biol Chem 233: 184–188
Hinegardner RT (1971) An improved fluorimetric assay for DNA. Anal Biochem 39: 197–201
Sandler S, Andersson A (1987) Cryopreservation of mouse pancreatic islets: effects of different glucose concentrations in the post-thaw culture medium on islet recovery. Cryobiology 24: 285–291
Bolaffi JL, Nowlain RE, Cruz L, Grodsky GM (1986) Progressive damage of cultured pancreatic islets after single early exposure to streptozotocin. Diabetes 35: 1027–1033
Eizirik DL, Sandler S (1987) The partial protective effect of branched chain amino acids against streptozotocin-induced cytotoxicity to mouse pancreatic islets in vitro. Pharmacol Toxicol 61: 320–324
Pipeleers D, Van de Winkel M (1986) Pancreatic B cells possess defense mechanisms against cell-specific toxicity. Proc Natl Acad Sci USA 83: 5267–5271
West DB, Seino Y, Woods SC, Porte D Jr (1980) Ventromedial hypothalamic lesions increase pancreatic sensitivity to streptozotocin in rats. Diabetes 29: 948–951
Iwatsuka H, Shino A, Taketomi S (1974) Streptozotocin resistance of the genetically diabetic KK mouse. Diabetes 23: 856–857
Talwalker PK, Kaul CL, Grewal RS (1979) Potentiation of the diabetogenic effect of Streptozotocin by phentolamine in the rat. J Pharm Pharmacol 31: 598–600
Nakadate T, Nakaki T, Muraki T, Kato R (1981) Adrenergic receptors and the onset of streptozotocin-induced diabetes in mice. Eur J Pharmacol 75: 45–51
Mandrup-Poulsen T, Spinas GA, Prowse SI, Hansen BS, Jorgensen DW, Bendtzen K, Nielsen JH, Nerup J (1987) Islet cytotoxicity of interleukin 1. Influence of culture conditions and islet donor characteristics. Diabetes 36: 641–647
Spinas GA, Palmer JP, Mandrup-Poulsen T, Nielsen JH, Andersson H, Nerup J (1987) Interleukin-1 exerts bimodal effects on insulin release from rat islets depending on dose, exposure time and ambient glucose concentration. Diabetologia 30: 584A (Abstract)
Eizirik DL, Sandler S, Welsh N, Hellerström C (1988) Preferential reduction of insulin production in mouse pancreatic islets maintained in culture after Streptozotocin exposure. Endocrinology 122 (in press)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Eizirik, D.L., Strandell, E. & Sandler, S. Culture of mouse pancreatic islets in different glucose concentrations modifies B cell sensitivity to streptozotocin. Diabetologia 31, 168–174 (1988). https://doi.org/10.1007/BF00276851
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00276851